Boothbay Fund Management
ITCI icon

Boothbay Fund Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Boothbay Fund Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-63,819
Closed -$8.42M – 1874
2025
Q1 		$8.42M Buy
+63,819
New +$7.95M 0.22% 102
2024
Q2 		– Sell
-5,700
Closed -$394K – 1916
2024
Q1 		$394K Buy
+5,700
New +$392K 0.01% 1097
2021
Q4 		– Sell
-19,851
Closed -$740K – 2294
2021
Q3 		$740K Sell
19,851
-19,219
-49% -$668K 0.02% 898
2021
Q2 		$1.59M Hold
39,070
– – 0.05% 485
2021
Q1 		$1.33M Buy
39,070
+2,528
+7% +$87.7K 0.05% 478
2020
Q4 		$1.16M Sell
36,542
-9,505
-21% -$250K 0.04% 445
2020
Q3 		$1.18M Buy
+46,047
New +$1.05M 0.07% 380
2020
Q2 		– Sell
-61,884
Closed -$1.25M – 1128
2020
Q1 		$951K Buy
+61,884
New +$1.34M 0.08% 315
2018
Q4 		– Sell
-17,000
Closed -$369K – 939
2018
Q3 		$369K Buy
+17,000
New +$355K 0.04% 452
2018
Q2 		– Sell
-11,300
Closed -$238K – 929
2018
Q1 		$238K Buy
+11,300
New +$220K 0.03% 553
2017
Q1 		– Sell
-12,303
Closed -$186K – 976
2016
Q4 		$186K Buy
+12,303
New +$174K 0.04% 617

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Huntington National Bank
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Boothbay Fund Management's ITCI Position: Q2 2025 in Review

Boothbay Fund Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 63,819 shares — an estimated $8.42M sold.

Boothbay Fund Management first reported a position in ITCI in Q4 2016 and held it in 11 quarters. The position peaked at $8.42M in Q1 2025. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Boothbay Fund Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 63,819 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $8.42M.
  • Boothbay Fund Management first reported a position in Intra-Cellular Therapies Inc. in Q4 2016 and held it in 11 quarters.
  • Boothbay Fund Management's Intra-Cellular Therapies Inc. position peaked at $8.42M in Q1 2025.
  • 3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Boothbay Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.